2024-08 – Q2 2024 Reporting
Contacts to banks for assisting Serodus in selling Serodus AS, the pipeline or the individual assets was initiated. Database for SER150 CL-009 is expected to be unblinded late August or…
Contacts to banks for assisting Serodus in selling Serodus AS, the pipeline or the individual assets was initiated. Database for SER150 CL-009 is expected to be unblinded late August or…
Serodus ASA - Publishes 2023 Annual Report Download it here
As a consequence of Board decision in December 2023, screening of new patients is stopped. The last patient last visit will be August 2024. Report expected to be finalized in…
After an initial increasing in screening and randomization activities of patients to the SER150 CL-009 study in New Zealand this has slowed down. Recruitment of patients in Australia remains very…
Screening of patients in New Zealand improved after visiting the clinical centres involved in SER150 CL-009 study. The broaden of inclusion criteria for recruitment of patients to theSER150 CL-009 study…
Screening of patients in New Zealand has now improved after visiting the clinical centres involved in SER150 CL-009 study. To facilitate enrolment, the entrance criteria will be revised for the…
Address: Stokholmsgade 412100 Copenhagen E June 21, 2023, at 15:00Please reserve the date